New research hints at a step beyond 3D printing in making customized implants. Researchers are working on a new material that changes shape when heated and could be used to surgically fill gaps in bone.
A couple of major players are making moves to get wearable med tech a bit closer to reality. Intel has partnered with the Michael J. Fox Foundation to collect data via smartwatches on Parkinson's disease patients, tracking the progression of disease.
A Phase III late-stage myeloma miss for Amgen's Kyprolis didn't shock analysts, who said the failure was more or less expected when the company announced trial results Wednesday. But without proof that the med prolongs life in those patients, getting Kyprolis by European regulators could be a tough sell.
Biosimilars promise huge potential, with estimates for this decade running from $35 billion to $200 billion and growing exponentially from there. And of course the U.S., being the world's largest pharma market, presents the greatest potential, once someone breaks in and acceptance can be judged.
San Diego's Otonomy pulled off a $100 million Wall Street debut, lining its pockets as it works to get a late-stage ear treatment through the FDA and onto the market.
A bioengineering professor says he has developed nanoparticles that can carry cancer-fighting insect toxins directly to tumors, sparing the rest of the body from nasty side effects, including damage to the heart, bleeding underneath the skin and unwanted clotting.
Researchers at the University of Washington have developed a medicated, electrospun fabric that could prevent HIV infections in women.
Researchers say they successfully tested in mice a molecular implant that contains gene-based mechanisms for delivering insulin based on feedback from an associated pH biosensor. By maintaining a healthy pH level between 7.35 and 7.45, the therapy, consisting of different genes and proteins, would prevent potentially fatal metabolic shock (ketoacidosis) in diabetics.
Prosensa, one of a handful of biotechs racing to develop treatments for Duchenne muscular dystrophy, has secured $7 million from a nonprofit to accelerate its R&D efforts.
Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.